Login
$TXMD
$1.83 +$0.02 (1.08%) After hours

$TXMD 8-K SEC Filings

Filed On Filing
13 Nov 2026 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
11 Aug 2026 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

BOCA RATON, Fla.--(BUSINESS WIRE)—August 11, 2026 -- TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the three months e...

12 May 2026 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

BOCA RATON, Fla.--(BUSINESS WIRE)—May 12, 2026 -- TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the three months ende...

30 Mar 2026 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

BOCA RATON, Fla.--(BUSINESS WIRE)—March 30, 2026 -- TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the full year ended...

21 Jan 2026 8-K: Changes in Registrant's Certifying Accountant

We are the former independent registered public accounting firm for TherapeuticsMD, Inc. (the “Company”).

16 Dec 2025 8-K: Submission of Matters to a Vote of Security Holders

On December 15, 2025, TherapeuticsMD, Inc., a Nevada corporation (the “Company”), held its 2025 Annual Meeting (the “Annual Meeting”). At the close of business on October 20, 2025, the record date for the determination of stockholders en...

13 Nov 2025 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

BOCA RATON, Fla.--(BUSINESS WIRE)—November 12, 2025 -- TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the three months...

12 Aug 2025 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

BOCA RATON, Fla.--(BUSINESS WIRE)—August 12, 2025 -- TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the three months e...

13 May 2025 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

BOCA RATON, Fla.--(BUSINESS WIRE)—May 13, 2025 -- TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the three months ende...

09 Apr 2025 8-K: Other Events

On April 8, 2025, TherapeuticsMD, Inc., a Nevada corporation (the “Company”), filed a lawsuit against Mayne Pharma LLC (“Mayne Pharma”) in the United States District Court for the District of Delaware (the “Mayne Lawsuit”) seeking damage...

27 Mar 2025 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

BOCA RATON, Fla.--(BUSINESS WIRE)—March 27, 2025 -- TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the full year ended...

05 Dec 2024 8-K: Submission of Matters to a Vote of Security Holders

On December 5, 2024, TherapeuticsMD, Inc., a Nevada corporation (the “Company”), held its 2024 Annual Meeting (the “Annual Meeting”). At the close of business on October 17, 2024, the record date for the determination of stockholders ent...

12 Nov 2024 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

BOCA RATON, Fla.--(BUSINESS WIRE)—November 12, 2024 -- TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the third quarte...

20 Sep 2024 8-K: Shareholder Director Nominations

TherapeuticsMD, Inc., a Nevada corporation (the “Company”), will hold its 2024 Annual Meeting of Stockholders (the “2024 Annual Meeting”) on Thursday, December 5, 2024. Holders of record of the Company’s common stock outstanding as of th...

12 Aug 2024 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

BOCA RATON, Fla.--(BUSINESS WIRE)—August 12, 2024 -- TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the second quarter...

10 May 2024 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

BOCA RATON, Fla.--(BUSINESS WIRE)—May 10, 2024-- TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the first quarter ende...

29 Mar 2024 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

BOCA RATON, Fla.--(BUSINESS WIRE)--Mar. 29, 2024-- TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the full year ended ...

14 Nov 2023 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

Focus remains on cost control to maximize the value of our royalty assets

18 Aug 2023 8-K: Entry into a Material Definitive Agreement; Departure/Election of Directors or Officers; Compensation

On August 15, 2023 (the “Effective Date”), TherapeuticsMD, Inc., a Nevada corporation (the “Company”), entered into a Master Services Agreement (the “Master Services Agreement”) with JZ Advisory Group (“JZ”), pursuant to which, among oth...

14 Aug 2023 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

BOCA RATON, Fla. – August 14, 2023 – TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the second quarter ended June 30, ...

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support